Organogenesis Holdings Inc.
Organogenesis Holdings Inc. develops, manufactures, and sells regenerative medicine products for advanced wound care and for surgical and sports medicine uses. Its portfolio includes tissue-based and cell-based products used by hospitals, wound care centers, ambulatory surgery centers, physician offices, and government facilities, with most sales generated in the United States and additional commercial activity in select international markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueBiologic and tissue-based products used to support healing of chronic and complex wounds.
Products used in surgical procedures and orthopedic or sports medicine applications.
Commercial sales of selected products in markets outside the United States.
Products
Reported · share of revenue- Products99.8 %
- Grant0.2 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Organogenesis sells primarily to healthcare providers that treat chronic wounds or perform procedures requiring regenerative tissue products. Its customer base includes hospitals, wound care centers, government facilities, ambulatory surgery centers, and physician offices, with purchasing driven by clinical use, reimbursement, and product availability.
Buy advanced wound care and surgical products for procedure-based healing and inpatient/outpatient use.
Purchase skin substitutes and biologics for chronic wound treatment protocols.
Use surgical and sports medicine tissue products in outpatient procedures.
Buy products for office-based wound management and follow-up care.
Purchase through public healthcare channels where reimbursement and coverage rules matter.
Strategy
Organogenesis focuses on expanding clinical evidence for its products, because outcomes data supports physician adoption and reimbursement positioning. It also invests in direct sales coverage, manufacturing capability, and selective international commercialization while maintaining a portfolio across wound care and surgical applications.
Evidence supports physician confidence, payer coverage, and product differentiation.
The company relies on direct sales relationships and field coverage to drive utilization.
Production capacity and facility readiness support growth and product availability.
International registrations can extend the product portfolio beyond the U.S. market.
Geography
The company is primarily a U.S. business, and its direct sales force in the United States represents the core of revenue generation. It also sells selected products in Switzerland and through distributors or agents in Saudi Arabia, Kuwait, and Mexico, with additional international expansion opportunities under evaluation, including the European Union.
Risks
The business is exposed to reimbursement decisions, especially Medicare coverage and payment policy for skin substitute products, because customer demand depends on payer support. It also faces intense competition, regulatory requirements, and execution risk in manufacturing, sales coverage, and information systems, all of which can affect product adoption and operating performance.
- Medicare coverage and reimbursement changesImpact: HighLikelihood: High
Demand for wound care products depends heavily on payer payment policy and coverage decisions.
Exposure: Advanced wound care and skin substitute products
- Proposed non-coverage LCDs for certain productsImpact: HighLikelihood: High
If finalized, non-coverage could reduce utilization of specific products in Medicare populations.
Exposure: Skin substitute grafts/CTPs for DFUs and VLUs
- Regulatory and quality complianceImpact: HighLikelihood: Medium
FDA and other healthcare regulations govern product approvals, manufacturing, and distribution.
Exposure - Intense competition and product substitutionImpact: MediumLikelihood: High
The company competes against skin substitutes, placental-based products, and traditional wound care.
Exposure: Advanced wound care and surgical markets
- IT and information security disruptionsImpact: MediumLikelihood: Low
Operational systems support sales, manufacturing, and customer service, so outages can impair execution.
Exposure: Commercial and manufacturing infrastructure
Accounting
Judgemental itemsRevenue can be recorded on procedure date, shipment, or delivery depending on contract terms.
Impact: Affects quarterly revenue comparability and reported growth rates
These deductions are recorded against gross sales and require estimation.
Impact: Affects net revenue and margin presentation
Fourth-quarter hospital buying is typically stronger due to budget cycles and deductibles.
Impact: Creates uneven quarterly revenue and working capital patterns
Management cites goodwill, long-lived assets, leases, and taxes as judgment-heavy areas.
Impact: Can materially affect earnings and balance sheet values
Similar listed companies
Publicly listed companies with a comparable business focus.
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
Regenerex Pharma, Inc.
Pharmaceutical Preparations
Celularity Inc
CELU · Pharmaceutical Preparations
Oragenics Inc
OGEN · Pharmaceutical Preparations
Regenerative Medical Technology Group Inc.
RMTG · Retail-Retail Stores, NEC
Organon & Co.
OGN · Pharmaceutical Preparations
Last updated: 24/09/2026